ED
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth
Latest NAV
+17.80% 1Y
Sign In to Add to Portfolio
Benchmark: MSCI India Domestic & World Healthcare 45 Index
Expense ratio
0.56%
AUM
₹200 Cr
Min SIP
₹100
Min lump sum
₹100
1Y
+17.80%
3Y (ann.)
+18.56%
5Y (ann.)
+13.57%
Launched
Oct 2020
Where the NAV sits & how risky it is
₹24.15
52-week range
at 77%
₹24.15
Low 08 Oct 2025₹20.65
High 31 Aug 2026₹25.20
Risk level
Very High
Low
Very high
NAV history
03 Nov 2020
Since inception
01 Oct 2026
Returns by period
1W
-3.64%
1M
-3.20%
3M
+2.18%
6M
+15.01%
1Y
+17.80%
3Y
+18.56%
5Y
+13.57%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 99.66%
Cash & other 0.34%
Sector split
Country split
Top 5 hold 34.3%
Top 10 hold 55.1%
45 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
11.42%
|
+4.52% |
| 2 | Eli Lilly and Co |
Healthcare Drug Manufacturers - General |
United States |
6.50%
|
+8.34% |
| 3 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
5.83%
|
+20.67% |
| 4 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.27%
|
+3.85% |
| 5 | Cipla
INE059A01026 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.24%
|
-8.03% |
| 6 | Max Healthcare Institute
INE027H01010 |
Healthcare Medical Care Facilities |
India |
4.97%
|
-3.35% |
| 7 | Dr Reddys Laboratories
INE089A01031 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.68%
|
+0.02% |
| 8 | Johnson & Johnson |
Healthcare Drug Manufacturers - General |
United States |
3.94%
|
+157.56% |
| 9 | Lupin
INE326A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.77%
|
+6.53% |
| 10 | Torrent Pharmaceuticals
INE685A01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.46%
|
+16.93% |
About this scheme
The Scheme will invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors. However, there is no assurance that the investment objective of the Scheme will be realized and the Scheme does not assure or guarantee any returns.
Fund manager(s): Bhavesh Jain, Amit Vora, Manasi Jalgaonkar
Exit load: No charges for withdrawal
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
26 Oct 2020
Lump-sum min
₹100
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
SBI Silver ETF FoF Direct Growth
1▲ 32.6 pts ahead of this fund
Kotak Silver ETF FoF Direct Growth
2▲ 31.7 pts ahead of this fund
Axis Silver FoF Direct Growth
3▲ 31.0 pts ahead of this fund
ICICI Prudential Strategic Metal and Energy Equity FoF Direct Growth
4▲ 31.0 pts ahead of this fund
DSP Silver ETF FoF Direct Growth
5▲ 30.9 pts ahead of this fund
Zerodha Silver ETF FoF Direct Growth
6▲ 30.9 pts ahead of this fund